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Background: Artemether-lumefantrine and artesunate-amodiaquine are first-line treatment for uncomplicated
malaria in Cameroon. No study has yet compared the efficacy of these drugs following the WHO recommended
42-day follow-up period. The goal of this study was to compare the clinical efficacy, tolerability and safety of
artesunate-amodiaquine (ASAQ), artemether-lumefantrine (AL) and dihydroartemisinin piperaquine (DHAP)
among children aged less than ten years in two malaria-endemic ecological regions of Cameroon.
Methods: A three-arm, randomized, controlled, non-inferiority trial was conducted among children of either gender
aged six months (>5 kg) to ten years (n = 720) with acute uncomplicated Plasmodium falciparum infection. Parents/
guardians of children provided consent prior to randomization to receive ASAQ, DHAP or AL in the ratio of 2:2:1,
respectively. Treatment outcome was assessed based on standard WHO 2003 classification after 42 days of follow-up.
The primary outcome was PCR-corrected day-42 cure rates. The non-inferiority, one-sided, lower limit asymptotic 97.5%
confidence interval (CI) on the difference in PCR-corrected cure rates of ASAQ and DHAP when compared to AL was
accepted if the lower limit of the CI was greater than −10%. Secondary outcomes were parasite and fever clearances
and day 7 haemoglobin changes.
Results: PCR-corrected PP cure rates of 96.7, 98.1 and 96.3, respectively, for AL, ASAQ and DHAP was observed. The
lower bound of the one-sided 97.5% CI calculated around the difference between day-42 cure rate point estimates in
AL and ASAQ groups, AL and DHAP groups were, −6% and −4% respectively. There were no statistical significant
differences in parasite or fever clearance times between treatments, although fever clearance pattern was different
between ASAQ and DHAP. No statistical significant differences were observed in the occurrence of adverse events
among treatment groups.
Conclusion: ASAQ and DHAP are considered safe and tolerable and are not inferior to AL in the treatment of
uncomplicated P. falciparum malaria in Cameroonian children.
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Although malaria mortality rates have fallen globally in
the Africa region [1], the disease continues to be a major
threat to childhood health and development. The ministry
of public health’s strategic plan for malaria control in
Cameroon in 2012, reports that malaria is responsible for
31, 44 and 18 percent of all consultations, hospitalizations
and deaths respectively, occurring in health facilities [2].
Efforts to curb malaria in the world have mainly been
through vector control and chemotherapy. Plasmodium
falciparum resistance to anti-malarials is a major drawback
in the effective control of the disease. Anti-malarial drugs,
such as chloroquine (CQ), sulphadoxine-pyrimethamine
(SP) and amodiaquine (AQ), which were once very active
against the malaria parasite, have been replaced by artemisi-
nin combination therapy (ACT) in many malaria-endemic
countries due to the emergence of resistance to these drugs
[3]. A study in 12 sentinel sites in Cameroon (1999–2004)
report CQ failure rates of 48.6% (irrespective of whether it
was early or late failure) compared to low failure rates of
7.3 and 9% for AQ and SP, respectively. At the end of 2002
until 2004, AQ and SP were selected as first-line treatment
and second-line treatment against falciparum malaria [4].
The association of a rapid acting and short elimination
half-life anti-malarial drug such as artemisinin deriva-
tives and a slower acting but longer half-life partner
drug would provide the best combination to delay the
onset of drug resistance [5]. The principal drugs recom-
mended to slow the spread of resistance today are
artemisinin-based combinations that include lumefantrine,
piperaquine, AQ and SP as accompanying drugs. Some of
these drugs, developed in Asia, were introduced into the
African market without broad-based efficacy testing in
different ecological sites. Cameroon adopted artesunate-
amodiaquine (ASAQ) and artemether-lumefantrine (AL)
as first-line treatments for falciparum malaria in 2006 [6].
No national evidence guided the choice of one artemisinin
combination over the other.
A few studies have been conducted on comparative
efficacy and safety of ACT in Cameroon. All evaluate
efficacy within 28 days based on WHO 2003 guidelines
for evaluating drug efficacy [7]. Whegang et al. [8] com-
pared the efficacy of a comprehensive list of monother-
apies and artemisinin combinations between 2003–2007
(including AL, ASAQ and dihydroartemisinin pipera-
quine (DHAP). Their results have shown generally high
PCR-corrected cure rates with all forms of ACT (artemi-
sinin combination therapy), with AL in the lead [8].
Despite the change in policy to ASAQ and AL as first-
line drugs for uncomplicated P. falciparum malaria and
the evidence of higher cure rates of AL over other forms
of ACT reported in a 28-day follow-up, DHAP (Atekin®) is
still sold in the drug stores in Cameroon [9]. The aim of
this study is to investigate the efficacy of AL, ASAQ andDHAP during a 42 days follow-up period and to assess the
non inferiority of ASAQ and DHAP when compared to
AL in Cameroon children less than ten years of age.
Methods
Study sites
In order to minimize the evaluation bias due to differences
in ecological regions, participants were recruited from
Cameroon’s two distinct ecological regions (Mutengene in
the Southwest region and Garoua in the North region).
These are regions of low to moderate transmission.
Mutengene is situated at 04°01’N, 09°11’E with an Equa-
torial climate and 10,000 mm of rainfall per annum with an
average temperature of 25°C. The vegetation is semi-
mangrove and tropical wet forest. The study site is limited
to the south and southeast by the sea and to the north
and northeast by Mount Cameroon, an active volcano
that is 4,100 m above sea level. The population works
predominantly on palm and rubber estates owned by
an agro-industrial complex known as the Cameroon
Development Corporation (CDC). The women and
children who do not work on these plantations engage
in farm work and/or fishing.
Garoua lies at 06°24’N, 10°46’E, and serves as a river
port in years when the rainfall is abundant. Situated in
the River Benue basin, it receives an average annual rain-
fall of 380 mm. It has about four months of rainy season.
Temperatures average 31°C for most of the year and the
vegetation is guinea-savannah. The population is predom-
inantly Muslim and comprised mainly of cattle raisers.
Study design
This study was a three-arm, open-labelled, randomized,
controlled, non-inferiority trial comparing the efficacy,
safety and tolerability of ASAQ and DHAP to AL in chil-
dren aged six to 120 months following a 42-day follow-up
period.
Sample size
The sample size for this study was calculated a priori
the assumption that AL would have a cure rate above
94%. To demonstrate with 95% confidence (α = 0.05)
that ASAQ or DHAP were acceptable if they are at
worse 10% (d) inferior in the occurrence of failures, 10%
risk (β) is accepted to rule out the null hypothesis of the
lack of inferiority.
Using the formula with f (α, β) statistics: N (sample
size) = [2p × (100 − p) × f(a, b)]/d2 [10]
¼ 2 94 6 10:5ð Þ=102
¼ 118 individuals in the smallest arm
Considering that other trials have reported loss to
follow-up and withdrawal rates of 10% in 28 days’ follow-
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42 days’ follow-up was reasonable. This allowed that a
minimum of 142 cases for the AL arm, and 284 cases
for each of the two tested arms (Coarsucam® and
Duo-cotecxin®) would be required, to make a total of 710
participants for all study sites. For the purposes of block
randomization, a sample size of 720 was preferred.
Study procedures
Participant enrolment
Children of either gender between the ages of six
months and ten years with a minimum weight of 5 kg,
meeting the inclusion criteria and who did not fulfil any
of the exclusion criteria, were enrolled. Participants were
enrolled if they were microscopically (using Giemsa-
stained thick film) confirmed with acute uncomplicated
P. falciparum malaria (1,000-100,000 parasites/μl), fever
with an axillary temperature ≥37.5°C, ability to ingest
tablets orally, and an assent from parents or guardians
to attend the clinic on follow-up visits. Exclusion criteria
included having any criteria for severe malaria, inability
to drink or breastfeed, persistent vomiting, convulsion,
unrousable coma, prostration, hypersensitivity to the
study drugs, severe gastrointestinal disease or malnu-
trition (weight for height <70%), severe anaemia
(haemoglobin <5 g/dl), and any other clinically severe
condition as judged by the trial physician. The first
patient was enrolled in 2009 and the final patient was
enrolled in April 2013
Randomization
A randomization list was produced according to a
randomization allocation schedule generated by a
computer-based randomization program [11]. Allocation
of participants was concealed in opaque envelopes that
were opened sequentially by the study physician once
consent was provided. The children were allocated
DHAP, ASAQ or AL according to the ratio 2:2:1. The
randomization number was recorded on the case re-
port form as the study identification code and used in
labelling all study-related laboratory samples.
Treatment and follow-up
AL (Coartem®: Novartis, Switzerland) tablets were pro-
vided in blister packs. Each tablet contains 20 mg arte-
mether and 120 mg lumefantrine. Prescription was
based on the weight of the child according to the recom-
mended guidelines (5 to <15 kg (20/120 mg or one
tablet), 15 to < 25 kg (40/240 mg or two tablets) and 25
to <36 kg (60/360 mg or three tablets) with second dose
administered eight hours later and then twice daily for the
subsequent two days. The AL was administered to-
gether with 200 ml of milk. ASAQ (Coarsucam®: Sanofi-
Aventis, France) was available in three presentations andprescribed based on age groups and weights. Each partici-
pant received one dose in the arm of the co-formulated
medication per day for three days (≥4.5 to < 9 kg (25 mg/
67.5 mg) one tablet/dose; ≥9 to < 18 kg (50 mg/135 mg)
one tablet/dose; ≥18 to < 36 kg (100 mg/270 mg) one tab-
let/dose. DHAP (Duo Cotecxin) was also a co-formulated
medication presented as scored tablets of 40 mg dihy-
droartemisinin and 320 mg piperaquine phosphate
each. Administration was based on recommended
doses (2.25 mg/kg dihydroartemisinin and 18 mg/kg
piperaquine per dose, rounded to the nearest half
tablet) with each child receiving one dose per day for
three consecutive days according to body weight. A
child received a replacement dose if vomiting occurred
less than 30 minutes after ingestion.
To ensure treatment compliance and to facilitate the
supervised administration of the study drugs and full
clinical and laboratory assessments and observation of
early adverse effects, treatment administration was by
direct observation on days 1, 2 and 3. All patients who
completed their treatment were asked to report to the
study clinic on days 7, 14, 21, 28, 35, and 42, or at any
other time they felt unwell. Those who failed to adhere
were visited by a community health worker and assisted
to perform scheduled activities. Prior to drug adminis-
tration, the study clinician made a clinical assessment of
the patient and recorded all observations in the trials’
register and hospital patient file before transfer into the
case report form. Abstracted data from hospital records
were rechecked by a study site coordinator to ensure
accuracy.
Laboratory analysis
Giemsa-stained thick blood films were prepared from
capillary blood and examined under a microscope for
determination of parasitaemia on all visit days and for
all unscheduled visits. Parasitaemia was quantified by a
standard approximation method (40 × the number of
parasites per 200 leukocytes on thick film). Quality con-
trol of the microscopy readings was done by mask
reading of 10% of the slides by a reference laboratory.
Haemoglobin levels were measured on days 0, 7 and 42
and on any unscheduled visit using a HemoCue B-
Hemoglobinometer (Hemocue®, Sweden). A full blood
count, including differentials and biochemical parame-
ters of liver and kidney function (alanine aminotransferase
serum activity, bilirubin and creatinine serum concentra-
tions), were investigated from in venous blood before
treatment and on days 7 and 42 or on the day of re-
appearance of parasitaemia. Any value that was found to
be significantly greater than twice the upper normal limit
was rechecked weekly until normal values were obtained.
Blood samples were collected and spotted onto filter pa-
pers (3MM; Whatman®) for parasite genotyping on days 0,
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days. DNA (both for human genomic DNA and parasite)
was extracted from blood spots on filter papers (What-
mann 3MM) by boiling in chelex-100 as described by
Plowe et al. [12]. PCR analysis of polymorphic antigen
markers including merozoite surface protein (MSP)-1,
MSP-2 and glutamate-rich protein (GLURP) were used to
distinguish parasites that were re-infecting from those that
were recrudescent in all parasite recurrent infections dur-
ing the period of follow-up. Recurrent parasite infections
that contained both recrudescent and re-infecting para-
sites were considered recrudescent to simplify analysis.
Outcome assessment
Evaluation of therapeutic outcome was based on WHO
guidelines on 42 days of follow-up [7]. The primary
efficacy outcome was the proportion of patients with a
PCR-corrected adequate clinical and parasitological
response (ACPR) after a follow-up of 42 days. Based on
these guidelines, ACPR was defined as the absence of para-
sitaemia on day 42 irrespective of axillary temperature,
without previously meeting any of the criteria for early
treatment failure (ETF), late treatment failure (LTF) or late
parasitological failure (LPF). ETF was defined as develop-
ment of danger signs of malaria on days 0, 1, 2 or 3 follow-
ing ingestion of drug, with parasitaemia greater than day 0
value on day 2 or any parasitaemic on day 3 greater than
25% of the day 0 value irrespective of axillary temperature
or any parasitaemia with axillary temperature ≥37.5°C on
day 3. Late treatment failure is defined by the same guide-
lines as presence of parasitaemia with axillary temperature
greater than 37.5°C between days 4 and 42 and without
meeting any of the criteria for ETF. LPF was defined to be
the presence of microscopic parasites on any day after day
7 with axillary temperature less than 37.5°C and without
meeting any of the criteria for ETF and LTF. The cure rate
was defined as the proportion of children with ACPR after
due 42 days of follow-up.
The secondary efficacy end points of the study were to
evaluate the efficacy of ASAQ, DHAP in comparison
with AL on day 14 (D14) and day 28 (D28) and day 42
fever clearance and parasite times (FCT and PCT, re-
spectively). FCT was defined as time (days) from the first
dose until the first time (days) the body temperature de-
creases below and remained below 37.5°C for at least
48 hours, while PCT was defined as time (in days)
from first dose until first total and continued dis-
appearance of microscopic asexual parasitaemia for at
least 48 hours. Therefore PCT and FCT were investi-
gated on days 1, 2 and 3.
Safety was determined by comparing notified or
reported adverse events (AEs) following treatment and
during the follow-up period. An adverse event was
defined according to the International Conference onHarmonization guidelines as any untoward medical
occurrences in a patient administered a pharmaceut-
ical product and which does not necessarily have a
causal relationship to the treatment. Severe AEs are
untoward medical occurrences that at any dose, result
in death, are life threatening, require hospitalization,
prolongation of existing hospitalization or result in
persistent and significant disability, or is a congenital
anomaly/birth defect.
Statistical analysis
Data were entered using Microsoft Office Access. Statistical
software SPSS version 17 (Somers, NY, USA) was used for
data management and processing. Data were analysed using
the software ‘R’ version 2.11.1. The primary efficacy out-
comes were analysed using both the intention-to-treat
(ITT) and per-protocol (PP) data sets. The ITT population
was made of all patients who received at least one dose of
study drug. Participants who deviated from study protocol
were included in the analyses. PP analyses included patients
who adhered to the protocol until attainment of an end
point or 42 days’ post-treatment. PCR-adjusted cure rates
between treatments were compared using χ2 test as well as
the odds ratios for likelihood of cure with 95% confidence
intervals (CIs). Similarly, safety variables were analysed
using ITT data. Comparison of categorical variables was
analysed using χ2 test (or Fisher’s exact test as appropriate).
Continuous data were tested for normality (Shapiro Wilk
test). Normally distributed data were analysed using the t-
test (or paired t-test where appropriate) or ANOVA and for
non-normal data, Wilkoxon rank test and Kruskall Wallis
test (for more than two groups) was used.
Non-inferiority of ASAQ and DHAP compared to AL
was assessed by constructing a one sided, lower limit
asymptotic 97.5% CI on the difference of PCR-corrected
cure rates of ASAQ and DHAP when compared to AL.
Non-inferiority was declared if the lower limit of the CI
was greater than −10% (for ASAQ or DHAP minus AL).
A P-value less than alpha = 0.05 was considered statisti-
cally significant in all the analyses.
Ethical considerations
Ethical clearance for the study was obtained from the In-
stitutional Review Boards of the Cameroon Baptist Health
Services, the Biotechnology Centre of the University of
Yaoundé I, and the WHO Ethical Review Committee. A
Data Safety and Monitoring Board appointed for the study
met twice every year through the duration (2009-April
2013) of the study. The trial was monitored by a WHO/
TDR consultant clinical trial monitor to ensure that all
clinical trial activities were in compliance with Good
Clinical and Laboratory Practices and approved study proto-
col. The trial was registered in the NIH clinical trial registry
number NCT01845701.
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Patient flow and baseline characteristics
In total, 1,250 children were screened from which 720
were randomized and enrolled into the three treatment
arms (Figure 1). Of these 720, 23 declined immediately
after taking their first dose of the trial drug and thus 697
treatment outcomes were available in the ITT. Another
74 patients were censored during the course of the
42 days, mainly due to loss to follow-up and protocol
violation. Therefore, 623 outcomes were available in the
PP analysis (86.5% protocol compliance). There was no
statistical significant difference in baseline characteristics
(Table 1) at enrolment between the three treatment
arms.
Primary outcome: efficacy of treatment and non-inferiority
test
The AL, ASAQ and DHAP PCR adjusted cure rates in the
ITT analysis population were 92, 91 and 89%, respectivelyFigure 1 The trial profile.(Table 2). The lower bound of the one-sided 97.5% CI cal-
culated around the difference between day-42 cure rate
point estimates in AL and ASAQ groups, AL and DHAP
groups were, respectively (−0.05, 0.01) and (−0.04, 0.09).
The lower bounds of these intervals are therefore greater
than the pre-specified −10% non-inferiority margin. The
drugs also had high cure rates in PP analysis populations.
AL, ASAQ and DHAP had adjusted cure rates of 96.7,
98.1 and 96.3%, respectively (Table 2). No Statistical
significant difference in PCR adjusted cure rates was ob-
served between treatments. The lower bound of the one-
sided 97.5% CI calculated around the difference between
day-42 cure rate point estimates in AL and ASAQ groups,
AL and DHAP groups were, respectively (−0.06, 0.03) and
(−0.04, 0.05). Similarly, in the ITT analysis, the lower
bounds of these intervals were as well greater than the
pre-specified −10% non-inferiority margin.
Crude day-42 cure rates for AL, ASAQ and DHAP
were similar (p = 0.9 and p = 0.75) for both ITT and PP
Table 1 Baseline characteristics of randomized study participants (ITT population)
Characteristics ASAQ AL DHAP P-value
Age* (months) ± SD 55.35 ± 34.5 57.97 ± 33.8 54.88 ± 32.9 0.67
Weight* (kg) ± SD 16.9 ± 7.3 17.8 ± 7.7 16.9 ± 6.8 0.41
Axillary temperature* (°C) ± SD 38 ± 1.1 38 ± 1.1 37.8 ± 1.1 0.5
Haemoglobin* (g/dl) ± SD 10.4 ± 2.14 9.9 ± 2.1 9.9 ± 2.1 0.44
Parasite density** (/μl) 13,555 (1,040-100,000) 14,808 (1,060-100,000) 13,690 (1,040-100,000) 0.71
Creatinine (mg/l) 0.65 ± 0.46 0.73 ± 1 0.68 ± 0.72 0.48
ALAT (IU/l) 30 ± 52 25 ± 23 26 ± 28 0.81
Absolute neutrophil count /μl 47 ± 18 48 ± 19 47 ± 18 0.76
Sex (male: female) (145:131) (67:75) (142:137) 0.5
* = mean ± SD (standard deviation); ** = median and range; ALAT = alanine aminotransferase.
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rates for AL, ASAQ and DHAP were 80.4% (95% CI,
72.6-86.4), 81.4% (95% CI, 76.1-85.7) and 80.4% (95% CI,
75.1-85.7), respectively. PP crude percentage cure rates
were higher that the crude ITT cures with AL, ASAQ
and DHAP having cure rates of 91% (95% CI, 84.2-95.2),
89.4% (95% CI, 84.8-92.7) and 89.4% (95% CI, 84.6-92.8),
respectively. The PCR-corrected cure rates were gener-
ally higher than crude cure rates. AL, ASAQ and DHAP
PCR-corrected percentage cure rates were 92% (95% CI,
85.9-95.7), 91% (95% CI, 89.3-95.7) and 89% (95% CI,
85.3-92.8), respectively for the ITT populations. PP
PCR-corrected percentage cure rates were 96.7% (95%
CI, 91.3-98.9), 98.1% (95% CI, 95.2-99.2) and 96.3% (95%
CI, 92.9-98.2) for AL, ASAQ and DHAP, respectively.
Secondary efficacy end points
Days 14 and 28 cure rates
Comparing therapeutic response outcomes for the differ-
ent treatment arms did not show any significant differ-
ence for both day 14 (p = 0.51) and 28 (p = 0.78) end
points, respectively (Table 3). No ETF was observedTable 2 Efficacy evaluation of AL(artemether
lumefantrine), ASAQ (artesunate amodiaquine) and
DHAP (dihydroartemisinin) in the treatment of
P. falciparum malaria in Cameroon children
ITT PP
Efficacy evaluation
No PCR correction n % 95% CI N % 95% CI
AL 138 80.4 72.6-86.4 123 91 84.2-95.2
ASAQ 279 81.4 76.1-85.7 255 89.4 84.8-92.7
DHAP 280 80.4 75.1-85.7 245 89.4 84.6-92.8
PCR corrected
AL 138 92 85.9-95.7 123 96.7 91.3-98.9
ASAQ 279 91 89.3-95.7 255 98.1 95.2-99.2
DHAP 280 89 85.3-92.8 245 96.3 92.9-98.2
ITT = intention to treat population; PP = per protocol population.among patients in the AL and ASAQ arm. Patients on
DHAP had a higher frequency of ETF and LCF.
Parasite and fever clearance patterns
Parasite clearance times were similar across the three
study arms (Figure 2A). However there appeared to be a
study site effect on parasite clearance, although not
significant. Most participants in Mutengene site (75%)
(Figure 2C), did not clear their parasites as measured by
microscopy by the end of day 1 post-treatment com-
pared to participants in Garoua (32%). Comparing the
parasite clearance time across the different treatment
arms and site did not show any significant difference by
day 3 post-treatment. There was a difference in fever
clearance patterns (Figure 2B) for the three treatment
arms (Mantel cox pairwise comparison; p = 0.04) be-
tween ASAQ and DHAP. However, no significant differ-
ence (p = 0.21) was found between the treatment groups
with respect to fever clearance time (FCT) at day 3.
Primary safety and tolerability outcomes
AEs frequency distribution among study participants
(Table 4) show that vomiting, cough, rashes, and an-
orexia were slightly higher in the group of participantsTable 3 PCR-adjusted therapeutic response (per protocol
analysis) for day 14 and day 28
Day 14 Day 28
Outcome AL ASAQ DHAP P-value AL ASAQ DHAP p-value
ACPR 119 250 236 0.51* 119 243 236 0.78*
ETF 0 0 2 0 0 2
LTF 1 2 4 1 7 4
LPF 3 2 3 3 4 3
ACPR = adequate clinical and parasitological response; ETF = early
treatment failure.
LCF = late clinical failure; LPF = late parasitological failure; AL = artemether-
lumefantrine; DHAP = dihydroartemisinin-piperaquine; ASAQ = artesunate-
amodiaquine; * = Fischer exact test (significant if there is at least one
significant difference in therapy outcome level when comparing the three
treatment regimen).
Figure 2 Parasite and fever clearing patterns.
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not differ with respect to the type of AEs (all p values <
0.05). Although there was no significant statistical differ-
ence (P = 0.09) in the occurrence of all AEs when com-
paring the trial drugs, ASAQ (35.5%) and DHAP (37.9%)
had higher number of AEs than AL (27.5%). One serious
AE occurred involving a child who experienced severe
fatigue after AL ingestion. The severe AE was resolved
after a 3-day hospitalization and adequate clinical care.
There was a slight decrease in mean haemoglobin
levels in all treatment groups between days 0 and 7
(Table 5). However, the change was significant for
DHAP (p = 0.0001) and AL (p = 0.003). Similarly there
was a general slight increase in alanine transferase activ-
ity and creatinine levels in all treatment groups. Betweentreatments, no statistical significant difference was found
comparing these parameters (Table 5).
There was slight increase (but for patients in the AL
treatment arm where alanine transferase activity dropped
from 28.07 IU/L to 22.01 IU/L) in alanine transferase
activity and creatinine levels by day 7 post-treatment irre-
spective of the treatment group. Abnormal biological
values were not accompanied by persistent signs or symp-
toms suggestive of any serious AE.
Discussion
Many studies are looking at the comparative efficacy of
different forms of ACT in settings where the treatment
is most likely to be used [13]. These studies seek to bet-
ter inform malaria experts and health policy makers on
Table 4 Frequency of adverse events (mild to moderate-
WHO grading) from days 1–7 after treatment initiation
Adverse event AL ASAQ DHAP P value*
(Using ITT populations) (N = 138) (N = 279) (N = 280)
Abdominal pain–n(%) 5(3.6) 6(2.1) 13(4.60 0.26
Anorexia–n(%) 1(0.72) 8(2.9) 12(4.3) 0.13
Joint ache–n(%) 2(1.4) 2(0.71) 2(0.71) 0.71
Cough–n(%) 9(6.5) 13(4.7) 18(6.4) 0.61
Diarrhoea–n(%) 4(2.8) 8(2.8) 9(3.2) 0.96
Fatigue–n(%) 3(2.2) 7(2.5) 4(1.4) 0.65
Fever–n(%) 2(1.4) 6(2.2) 3(1.1) 0.58
Rash–n(%) 4(2.9) 18(6.4) 16(5.7) 0.31
Vomiting–n(%) 8(5.8) 31(11.1) 27(9.6) 0.21
TOTAL–n(%) 38(27.5) 99(35.5) 106(37.9) 0.09
*3 sample Chi-squared test for proportions with or without continuity
correction as appropriate; ITT = intention to treat.
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malaria-endemic countries [13-15]. In this study, the ef-
ficacy of ASAQ, DHAP and AL was compared in the
same population during the same period 42 days after
treatment administration. The drug had high cure rates
for days 14, 28 and 42. These results are consistent with
results from studies in other malaria-endemic countries
in sub-Saharan Africa [14,16,17] indicating the choice to
move to artemisinin-based combinations is appropriate
in the face of emerging resistance to other common
anti-malarials. The high cure rates are consistent in the
two sites with different ecologies and climatic condi-
tions. The high cure rates of these anti-malarial drugs
and the effective use of insecticide-treated bed nets
could significantly reduce morbidity and mortality in the
Cameroonian population [18].
This study shows similar ACT cure rates in Mutengene
and Garoua and supports the nationwide implementa-
tion of ACT irrespective of geographic location and
ethnicity and brings an added advantage towards
malaria elimination. The authorities in the Ministry of
Health in Cameroon are fighting the illicit sale ofTable 5 Evolution of biological parameters with respect to AL
Parameter AL ASAQ
DO D7 D0-D7 P* DO D7
Hb (g/dl) 10.2 9.56 0.46 0.003 10.4 9.92
[SD] [2.2] [1.93] [1.67] [6.90] [5.63
ALAT (IU/l) 28.07 22.01 6.05 0.114 23.59 29.61
[SD] [40.25] [16.16] [42.19] [19.30] [0.47
CREA (mg/l) 0.76 1.07 −0.31 0.476 0.65 0.68
[SD] [1.04] [4.74] [4.84] [0.03] [0.06
P* = paired t test, P== F test from anova (comparing difference across three drugs);
[SD] = Standard deviation, ALAT = alanine aminotransferase, CREA = Creatinine levelmedication by road vendors and unauthorized agents.
There is still wide circulation of competing drugs to
those enforced by the government for treating malaria
[1]. The situation is worsened with stock-outs of anti-
malarials at recognized distribution centres [19,20].
Patients are obliged to search for alternatives without
proper information on the source of anti-malarials, their
efficacy and tolerability. The non-inferiority of the study
drugs compared to widely used AL will enable caregivers
to make informed prescription decisions. The proper use
of alternative, available, efficacious and safe drugs is
helpful in delaying artemisinin resistance, which is be-
ginning to emerge [9].
Along with reports of emergence of drug resistance to
efficacious ACT, there is a need to closely monitor the
efficacy and safety of these drugs. One way to monitor
anti-malarial drug resistance in the absence of validated
molecular markers and appropriate in vitro models is by
analysing parasite clearance times [21]. Parasite clear-
ance time curves represented by the proportion of pa-
tients that clear parasites with respect to the time from
onset of treatment did not show any appreciable delay
across the three study drugs. Although parasite clear-
ance times were not measured by the standard defin-
ition, patients in Garoua had an advantage in their
parasite clearance time when compared to Mutengene
in all treatment arms in first two days during treatment.
Mutengene, located in the Equatorial forest, has malaria
transmission all year round whereas in Garoua transmis-
sion is seasonal and peaks within the rainy season. Dif-
ferences in clearance rates by day 2 post-treatment
therefore do not seem to be related to malaria exposure.
The day 0 geometric mean parasite densities across
treatment arms were comparable (Table 1). This may
point to a well-known phenomenon, that the Fulani are
more efficient at controlling parasites during early infec-
tion compared to non-Fulani [22,23]. The Fulani group
predominates in the northern Sahelian regions of
Cameroon, However, there is a clear need to further in-
vestigate parasite and fever clearance by the standard
definition of clearance time to gain a proper picture of, ASAQ and DHAP
DHAP
D0-D7 P* DO D7 D0-D7 P* P+
0.48 0.367 9.92 9.37 0.55 0.001 0.988
] [8.55] [2.15] [1.82] [1.79]
−0.61 0.134 25.75 35.33 −9.58 0.288 0.355
] [63.57] [2.62] [7.3] [14.67]
−0.03 0.565 0.71 1.1 −0.39 0.171 0.531
] [0.88] [0.72] [4.46] [4.52]
Hb = haemoglobin level.
.
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[22,24]. Difference in parasite susceptibility could be a
plausible reason as well. The proportion of patients with
a temperature below 37°C after the 3rd day of first treat-
ment and who remain so for the next 48 hours are simi-
lar across the different study drugs. Patients in the
ASAQ treatment group and DHAP treatment group
cleared their fever quicker than those in the AL group
three days after starting treatment (Figure 2B). This dif-
ference however only suggests that patients taking
ASAQ and DHAP, compared to AL were relieved of the
symptom much faster and this did not influence the out-
come of treatment.
There were no significant changes in levels of kidney
and liver function parameters measured (creatinine, ala-
nine aminotransferase) between days 0 and 7 across the
different treatment arms. Considering haemoglobin
changes post-treatment, a significant difference was ob-
served (Table 5) in the day 0 and day 7 haemoglobin
levels of patients in the AL and DHAP treatment arms.
However, as shown in Table 5, these changes were tran-
sient and all patients recovered by day 42 post-treatment
without any effect on the cure rates achieved. These
findings show that the drugs are well tolerated biologic-
ally as demonstrated in several other studies in malaria-
endemic areas [25].
Conclusion
ASAQ and DHAP were non inferior to AL in the treat-
ment of uncomplicated P. falciparum malaria in Camer-
oonian children under ten years old with PCR-42 day
corrected cure rates > 96%.
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